Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
SGLT2 inhibitor plus GLP-1 receptor agonist for cardiorenal metabolic syndrome
ChiCTR2500105669Phase 4Recruiting
- Sponsor
- Zhongshan Hospital, Fudan University
- Start
- Jul 2025
- Modality
- Recombinant Proteins and Enzymes, Peptides, Small Molecules
- Countries
- 1
01
Overview
Phase 4, open-label trial of dulaglutide, exenatide, liraglutide, semaglutide, canagliflozin and 2 more in cardiovascular-kidney-metabolic syndrome, cardiac morbidity, chronic kidney disease (CKD) and 1 more (3 arms), sponsored by Zhongshan Hospital, Fudan University. Primary endpoints: Major cardiovascular events (MACE) and Renal events. Started Jul 2025; status: recruiting.
02
Drugs
03
Conditions
cardiovascular-kidney-metabolic syndromecardiac morbiditychronic kidney disease (CKD)type 2 diabetes mellitus (T2DM)
Beyond the preview
Go deeper on ChiCTR2500105669.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2500105669.